Skip to main content
. 2014 Apr 30;5(22):11193–11208. doi: 10.18632/oncotarget.1933

Figure 7. Combination of PPP and ABT-737 equally targets CD138+ and CD138− MM subpopulations.

Figure 7

A: ABT-737 sensitivity of mature CD138+ and immature CD138− 5T33MM cells. Sorted populations were incubated with different concentrations of ABT-737 (0.5, 1 and 2 μM). Cell viability was analyzed after 24h by a CellTiter-Glo assay. B-C: Relative Bcl-2 (B) and Mcl-1 (C) mRNA expression in the 2 subpopulations. mRNA expression was evaluated by quantitative realtime RT-PCR. The Bcl-2 and Mcl-1 gene expression was normalized to GAPDH. Data are presented as relative mRNA expression compared to CD138+ cells. Bars and error bars indicate mean ± SD of 4 individual mice. D: Sensitivity of the CD138+ and CD138− 5T33MM cells to ABT-737 alone and in combination with PPP. Sorted populations were incubated with PPP (0.5, 1 and 2 μM), ABT-737 (0.5, 2 and 8 μM) or a combination of both. After 24h, the viability was measured by a CellTiter-Glo assay. Results are given as the percentage viability relative to control. Bars and error bars indicate mean ± SD of at least 3 independent experiments. * indicates p value of <0.05, ** p value of <0.01 comparing CD138− cells against CD138+ cells.